China’s Aoxing, U.S.’s American Oriental Pair To Market Painkillers
This article was originally published in PharmAsia News
China's Aoxing Pharmaceutical has signed an agreement with Oriental Bioengineering of the United States to develop and market painkillers and narcotics. The deal calls for American Oriental buying a 38 percent share of Aoxing for $18 million. Aoxing recently completed its acquisition of Shijazhuang Lerentang Pharmaceutical, also of China. Shijazhuang specializes in pain-management products. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.